The Next-Generation NF1 Models Initiative (NGMI) focuses on developing innovative NF1 preclinical models to enable more robust NF1 drug discovery and translation into human clinical trials.
See NGMI Advisory BoardThe creation of the Next-Generation NF1 Models Initiative (NGMI) addresses the need for more advanced models of NF1 disease, which are key to developing improved treatments.
The projects in the NGMI place a special emphasis on organoid, assembloid, and other in vitro 3D tissue and organ models, which are organ-like assemblies of tissues grown in a lab environment. These models add depth to mechanistic studies, which focus on the mechanism of action for a disease. They are also more tractable to drug screening, meaning researchers can more easily test whether a drug is more likely to be effective on any given disease target.
Additionally, NGMI includes some next-generation in vivo models focused on NF1-associated brain tumors, peripheral tumors, and behavioral manifestations related to the disease.